ReviewNature reviews. Gastroenterology & hepatology2010
Mechanisms of disease: Helicobacter pylori virulence factors.
Review in Nature reviews. Gastroenterology & hepatology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 326 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
326 citing papers in PubMed, 3 syntheses or guidelines pooled it, 656 citations in OpenAlex.
- Asian Pacific Association of Gastroenterology task force recommendations on surveillance forGut · 2026Guideline
- Helicobacter pylori cagA status and gastric mucosa-associated lymphoid tissue lymphoma: a systematic review and meta-analysis.Journal of health, population, and nutrition · 2022Pooled it
- Changing trends in the prevalence of H. pylori infection in Japan (1908-2003): a systematic review and meta-regression analysis of 170,752 individuals.Scientific reports · 2017Pooled it
- Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers.International journal of cancer · 2026Article
- Chestnut (Castanea sativa Mill.) leaf extract and pure castalagin reduce bacterial colonisation and the associated inflammation in gastric organoids and a mouse model of H. pylori infection.Inflammopharmacology · 2026Article
- Berberine and Berberine-Derived Compounds as Promising Weapons AgainstPharmaceuticals (Basel, Switzerland) · 2026Review
- Bad bugs mean business: gastric cancer is an intended consequence ofInfection and immunity · 2026Review
- Manuka honey as a multifunctional therapeutic against Helicobacter pylori: from chemical profiling to in vitro potency and in vivo gastroprotective efficacy.BMC complementary medicine and therapies · 2026Article
- Enhanced COMP expression induced by Helicobacter pylori drives gastric cancer progression by NOTCH2/SMAD3 pathway.Journal of gastroenterology · 2026Article
- Gastric Microbiota Dysbiosis and Microbiome-Based Interventions in Chronic Atrophic Gastritis.Nutrients · 2026Review
- Genomic characterization of clinical Helicobacter pylori strains from Korea: insights into phylogeny, pan-genome structure, and virulence factors.BMC microbiology · 2026Article
- Molecular characterization of H. pylori: genetic diversity and vacA s1m1/cagA+ prevalence in Western Algeria.Molecular genetics and genomics : MGG · 2026Article
- Immunokinetic signatures ofFrontiers in cellular and infection microbiology · 2026Review
- Article
- Beyond acid suppression: the multifaceted role of proton pump inhibitors inFrontiers in microbiology · 2026Review
- Quantifying the effects of the Correa pathway from Helicobacter pylori infection to gastric cancer: causal inference found in 6.8 million Koreans.BMC cancer · 2025Article
- Review
- Article
- Article
- Development of a multi-epitope vaccine against Helicobacter pylori using a novel saRNA technology through an immunoinformatics approach.Scientific reports · 2025Article
266 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Helicobacter pylori plays an essential role in the development of various gastroduodenal diseases; however, only a small proportion of people infected with H. pylori develop these diseases. Some populations that have a high prevalence of H. pylori infection also have a high incidence of gastric cancer (for example, in East Asia), whereas others do not (for example, in Africa and South Asia). Even within East Asia, the incidence of gastric cancer varies (decreasing in the south). H. pylori is a highly heterogeneous bacterium and its virulence varies geographically. Geographic differences in the incidence of gastric cancer can be explained, at least in part, by the presence of different types of H. pylori virulence factor, especially CagA, VacA and OipA. However, it is still unclear why the pathogenicity of H. pylori increased as it migrated from Africa to East Asia during the course of evolution. H. pylori infection is also thought to be involved in the development of duodenal ulcer, which is at the opposite end of the disease spectrum to gastric cancer. This discrepancy can be explained in part by the presence of H. pylori virulence factor DupA. Despite advances in our understanding of the development of H. pylori-related diseases, further work is required to clarify the roles of H. pylori virulence factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.